Julie Rubinstein Sells 19,060 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Posted by ABMN Staff on Mar 25th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $13.83, for a total value of $263,599.80. Following the sale, the chief operating officer directly owned 481,906 shares of the company’s stock, valued at approximately $6,664,759.98. This trade represents a 3.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Julie Rubinstein also recently made the following trade(s):

On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total transaction of $254,832.20.
On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total transaction of $251,210.80.
On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.41, for a total transaction of $255,594.60.
On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total transaction of $1,881,638.07.
On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total value of $247,017.60.
On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.79, for a total value of $457,617.39.
On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total value of $285,672.80.
On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT opened at $13.90 on Wednesday. The company has a market cap of $2.14 billion, a P/E ratio of -34.75 and a beta of 2.19. The stock has a 50-day moving average of $16.10 and a two-hundred day moving average of $15.92. Adaptive Biotechnologies Corporation has a 1-year low of $6.68 and a 1-year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. The business had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business’s quarterly revenue was up 51.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.23) earnings per share. On average, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. BTIG Research boosted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Guggenheim increased their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Read Our Latest Stock Analysis on ADPT

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $28,000. Sound Income Strategies LLC purchased a new stake in Adaptive Biotechnologies during the third quarter worth $30,000. EverSource Wealth Advisors LLC grew its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. grew its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $51,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.